NasdaqGS:JAZZPharmaceuticals
Jazz Pharmaceuticals (JAZZ) Quarterly Profit Of US$203 Million Tests Trailing Loss Narrative
Jazz Pharmaceuticals (JAZZ) just released its FY 2025 numbers, reporting Q4 revenue of US$1.2 billion and basic EPS of US$3.33, alongside trailing 12 month revenue of US$4.3 billion and a basic EPS loss of US$5.84. Over recent quarters, the company has reported revenue in a range from US$897.8 million in Q1 2025 to US$1.2 billion in Q4 2025, while quarterly basic EPS has moved between a loss of US$11.74 and a profit of US$4.14. This sets up a story where investors are weighing sizeable top...